AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25008857 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Mg/d (oral magnesium supplementation)
Number of subjects: 139
Study 25008857 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 139
Study 22721655 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1789
Study 22721655 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1789
Study 20398561 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d for 8 weeks
Number of subjects: 91
Study 18773688 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic variations of the middle nasal meatus
Number of subjects: 0
Study 18773688 — intervention group
Group type: EXPERIMENTAL
Intervention: Eives's correlation coefficient
Number of subjects: 0
Study 15625369 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin (GCa)
Number of subjects: 422
Study 15625369 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin, ifosfamide, and cisplatin (MIC)
Number of subjects: 422
Study 12679760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 1516
Study 12679760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 10695183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination (FDC) of rifampicin (RIF) and isoniazid (INH)
Number of subjects: 0
Study 10695183 — intervention group
Group type: COMPARATOR
Intervention: Separate formulation of rifampicin (RIF)
Number of subjects: 0
Study 10695183 — intervention group
Group type: COMPARATOR
Intervention: Imported FDC formulation of rifampicin (RIF) and isoniazid (INH)
Number of subjects: 0
Study 7562132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo method
Number of subjects: 71
Study 7562132 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 71
Study 1685666 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 50 mg
Number of subjects: 40
Study 1685666 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide 150 mg
Number of subjects: 40
Study 1685666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6759334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine 1 g t.i.d. for five days
Number of subjects: 0
Study 6759334 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 1 g t.i.d. for five days
Number of subjects: 0
Study 31859599 — intervention group
Group type: EXPERIMENTAL
Intervention: Indurometer
Number of subjects: 0
Study 30507217 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure (DV and CV)
Number of subjects: 72
Study 30596666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole 960 mg/tablet (CTX group)
Number of subjects: 2180
Study 30596666 — intervention group
Group type: COMPARATOR
Intervention: Daily oral placebo (PLC group)
Number of subjects: 2180
Study 27411788 — intervention group
Group type: COMPARATOR
Intervention: Usual care (operative care)
Number of subjects: 0
Study 27411788 — intervention group
Group type: COMPARATOR
Intervention: Restrictive strategy (stepwise selection for laparoscopic cholecystectomy)
Number of subjects: 0
Study 24529259 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led physical activity intervention (playground games 2 days a week and interactive console games 2 days a week for 6 months)
Number of subjects: 115
Study 24529259 — intervention group
Group type: COMPARATOR
Intervention: Control group (receives the intervention after serving as control)
Number of subjects: 115
Study 21691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200-600 mg with food
Number of subjects: 55
Study 21691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg with food
Number of subjects: 55
Study 21691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg with food
Number of subjects: 55
Study 21691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200-800 mg with food
Number of subjects: 55
Study 21691746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200-800 mg
Number of subjects: 55
Study 21691746 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib
Number of subjects: 55
Study 20398115 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage and guided meditation
Number of subjects: 167
Study 20398115 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group: patients without cancer)
Number of subjects: 167
Study 17572803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (40 mg once weekly)
Number of subjects: 138
Study 17572803 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron bis-glycinate chelate-enriched cookies (3.8 mg, 3x/week for 8 weeks)
Number of subjects: 138
Study 17572803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions for children with depleted iron stores (< 15 ng/mL)
Number of subjects: 138
Study 16294118 — intervention group
Group type: EXPERIMENTAL
Intervention: Single imputation using the EM algorithm
Number of subjects: 0
Study 16294118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI)
Number of subjects: 0
Study 16294118 — intervention group
Group type: COMPARATOR
Intervention: Observed data analysis approach
Number of subjects: 0
Study 11275038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy ball cauterization applied to the entire crater following excision (Group A)
Number of subjects: 101
Study 11275038 — intervention group
Group type: COMPARATOR
Intervention: No cauterization in a 2-3-mm zone around the new os (Group B)
Number of subjects: 101
Study 9263281 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d, divided in 3 doses of 10 g each) for 8 consecutive days during each interval between chemotherapy
Number of subjects: 65
Study 9263281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 65
Study 9263281 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 65
Study 9263281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 9263281 — intervention group
Group type: COMPARATOR
Intervention: Glutamine and Placebo
Number of subjects: 65
Study 8214727 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (75-micrograms bolus and infusion of 2.5 micrograms/mL at 15 mL/h)
Number of subjects: 130
Study 8214727 — intervention group
Group type: COMPARATOR
Intervention: Ultra low-dose bupivacaine (0.04%), epinephrine (1.7 micrograms/mL), and fentanyl (1.7 micrograms/mL) (15-mL bolus followed by infusion at 15 mL/h)
Number of subjects: 130
Study 2962088 — intervention group
Group type: EXPERIMENTAL
Intervention: Human hemi-synthetic insulin
Number of subjects: 54
Study 2962088 — intervention group
Group type: COMPARATOR
Intervention: Porcine MC-insulin
Number of subjects: 54
Study 31328671 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot therapy (RT) for 60 minutes
Number of subjects: 45
Study 31328671 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted transition-to-task training (TTT) for 45 minutes of RT plus 15 minutes of TTT
Number of subjects: 45
Study 31328671 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT
Number of subjects: 45
Study 31328671 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 45
Study 26757902 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud es Vida intervention (promotora-led educational group session)
Number of subjects: 90
Study 26757902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for relatives of people with mental health problems
Number of subjects: 50
Study 25770784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 24385355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei subsp. paracasei LC01 (10^10 CFU in 12% skimmed milk)
Number of subjects: 52
Study 24385355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skimmed milk without LC01)
Number of subjects: 52
Study 21444590 — intervention group
Group type: EXPERIMENTAL
Intervention: SEEK model (intervention group)
Number of subjects: 102
Study 18963721 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program (10 sessions)
Number of subjects: 73
Study 18963721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducation)
Number of subjects: 73
Study 16524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Original omeprazole (10 mg once daily after breakfast)
Number of subjects: 7
Study 16524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-Towa (10 mg once daily after breakfast)
Number of subjects: 7
Study 16524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Omerap (10 mg once daily after breakfast)
Number of subjects: 7
Study 16524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazon (10 mg once daily after breakfast)
Number of subjects: 7
Study 16524789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulanze (10 mg once daily after breakfast)
Number of subjects: 7
Study 16524789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 15194374 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed graft function (DGF) of the kidney
Number of subjects: 297
Study 15194374 — intervention group
Group type: COMPARATOR
Intervention: No delayed graft function (non-DGF)
Number of subjects: 297
Study 11422960 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐MPH assay
Number of subjects: 300
Study 9499939 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise of 75 dBA for 15 min
Number of subjects: 60
Study 9499939 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise of 75 dBA for 15 min with 0.25 mg of alprazolam (Xanax®) ingested 1 hr before
Number of subjects: 60
Study 9499939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of alprazolam (Xanax®) without noise exposure
Number of subjects: 60
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine
Number of subjects: 0
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 0
Study 8100058 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 0
Study 2831701 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-THC (doses of 2.5-15 mg)
Number of subjects: 13
Study 2831701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29574878 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (US)
Number of subjects: 224
Study 29574878 — intervention group
Group type: COMPARATOR
Intervention: Radiology ultrasound (US)
Number of subjects: 224
Study 27933161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) and leukotriene-receptor antagonist (LTRA)
Number of subjects: 158
Study 26311225 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 homozygotes for the wild type
Number of subjects: 408
Study 26311225 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 carriers of reduced function allele
Number of subjects: 408
Study 26311225 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 homozygotes for the reduced function allele
Number of subjects: 408
Study 23370067 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (RPMS)
Number of subjects: 13
Study 23370067 — intervention group
Group type: EXPERIMENTAL
Intervention: RPMS combined with training
Number of subjects: 13
Study 23370067 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 13
Study 21600100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing prosthesis
Number of subjects: 80
Study 21600100 — intervention group
Group type: COMPARATOR
Intervention: Mobile-bearing prosthesis
Number of subjects: 80
Study 18622483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Number of subjects: 10
Study 18622483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution
Number of subjects: 10
Study 17065936 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary block (20 children)
Number of subjects: 41
Study 17065936 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation with ketamine and midazolam (21 children)
Number of subjects: 41
Study 12861166 — intervention group
Group type: EXPERIMENTAL
Intervention: Postterm delivery
Number of subjects: 77956
Study 12861166 — intervention group
Group type: COMPARATOR
Intervention: Term delivery
Number of subjects: 77956
Study 10704956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycine (100 mg/kg or 200 mg/kg)
Number of subjects: 0
Study 10704956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-cycloserine (50 mg)
Number of subjects: 0
Study 10704956 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 10704956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycine
Number of subjects: 0
Study 10704956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D-cycloserine
Number of subjects: 0
Study 8167297 — intervention group
Group type: EXPERIMENTAL
Intervention: Technologies for early detection of end-point surrogates
Number of subjects: 1000000
Study 8167297 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale therapeutic trials of agents intended to alter outcome
Number of subjects: 1000000
Study 2514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group (all nonprotein calories as glucose)
Number of subjects: 24
Study 2514287 — intervention group
Group type: COMPARATOR
Intervention: Fat-glucose group (60% of nonprotein calories as fat emulsion)
Number of subjects: 24
Study 4616803 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoxate (600 mg daily)
Number of subjects: 60
Study 4616803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30916353 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet fed to ducks from 1 to 56 days
Number of subjects: 176
Study 28637705 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP functions fitted to HR data from 5MTs at 60% V˙O2 max (ET60)
Number of subjects: 41
Study 28637705 — intervention group
Group type: EXPERIMENTAL
Intervention: SIG functions fitted to HR data from 5MTs at 60% V˙O2 max (ET60)
Number of subjects: 41
Study 28637705 — intervention group
Group type: COMPARATOR
Intervention: EXP functions fitted to HR data from trained participants (ETabs) at 100W
Number of subjects: 41
Study 28637705 — intervention group
Group type: COMPARATOR
Intervention: SIG functions fitted to HR data from untrained participants (UTabs) at 100W
Number of subjects: 41
Study 25017938 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Personal Empowerment‐Headache Education Program (COPE‐HEP)
Number of subjects: 36
Study 25017938 — intervention group
Group type: COMPARATOR
Intervention: Headache education comparison group
Number of subjects: 36
Study 23978529 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT1)
Number of subjects: 68
Study 23978529 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (KT2)
Number of subjects: 68
Study 22689176 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Carboplatin plus Celecoxib (DCC)
Number of subjects: 196
Study 22689176 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus Carboplatin (DC)
Number of subjects: 196
Study 19766062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tent
Number of subjects: 120
Study 19766062 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 120
Study 17119458 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of salvaged autologous blood (n = 12)
Number of subjects: 24
Study 17119458 — intervention group
Group type: COMPARATOR
Intervention: Standard drain with no reinfusion (n = 12)
Number of subjects: 24
Study 15526107 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 20 mg/day for 7 days
Number of subjects: 0
Study 15526107 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol (20, 40 or 80 mg p.o.)
Number of subjects: 0
Study 15526107 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (beta(1)-adrenoceptor blocker)
Number of subjects: 0
Study 15526107 — intervention group
Group type: EXPERIMENTAL
Intervention: Post withdrawal of carteolol
Number of subjects: 0
Study 11606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare
Number of subjects: 37
Study 11606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone calls
Number of subjects: 37
Study 11606877 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study 9834280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting
Number of subjects: 80
Study 9834280 — intervention group
Group type: COMPARATOR
Intervention: No stents
Number of subjects: 80
Study 7720769 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% dorzolamide, approximately 7.7 micrograms per day (21.3 mumol) dorzolamide hydrochloride, administered bilaterally q.i.d. for 14 days
Number of subjects: 12
Study 7720769 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered bilaterally q.i.d. for 14 days
Number of subjects: 12
Study 7720769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide, 125 mg q.i.d.
Number of subjects: 12
Study 1904333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5, 10, 20, 40 mg
Number of subjects: 150
Study 1904333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 6118074 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG NC45 0.1 mg/kg
Number of subjects: 3
Study 6118074 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG NC45 0.15 mg/kg
Number of subjects: 3
Study 6118074 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 3
Study 30638076 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person 12-week prehabilitation program
Number of subjects: 34
Study 30638076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation program
Number of subjects: 34
Study 30638076 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 31618560 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Number of subjects: 168
Study 31618560 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (control group)
Number of subjects: 168
Study 28947003 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC–OCT segmentation method for automatic detection of lumen border in OCT images.
Number of subjects: 20
Study 28947003 — intervention group
Group type: COMPARATOR
Intervention: Ground-truth manual segmentation performed by experts.
Number of subjects: 20
Study 26135740 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 388
Study 26135740 — intervention group
Group type: COMPARATOR
Intervention: 4F-PCC
Number of subjects: 388
Study 23788751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day plus erlotinib 150 mg/day
Number of subjects: 132
Study 23788751 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg/day (placebo plus erlotinib)
Number of subjects: 132
Study 23788751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus erlotinib
Number of subjects: 132
Study 23788751 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 132
Study 21436147 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 68
Study 21436147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19668882 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphereline 3.75 mg, 4 times every 28 days (group I)
Number of subjects: 60
Study 19668882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg, once a week for 6 weeks (group II)
Number of subjects: 60
Study 17263895 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical training program
Number of subjects: 0
Study 17263895 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study 15514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium dose of 250 micromol Li
Number of subjects: 0
Study 15514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium dose of 213 micromol Li
Number of subjects: 0
Study 15514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium dose of 175 micromol Li
Number of subjects: 0
Study 15514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring serum Li 3-9 h after the last dose
Number of subjects: 0
Study 15514287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff value for serum Li
Number of subjects: 0
Study 11176734 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg twice daily for 5 days)
Number of subjects: 321
Study 11176734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 9779135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (100 ml 10% NaCl)
Number of subjects: 42
Study 8286206 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2)
Number of subjects: 80
Study 8286206 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone (3 million IU day-1 at 8.00 p.m. 6 days a week for 4 weeks)
Number of subjects: 80
Study 8286206 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT
Number of subjects: 80
Study 8286206 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 80
Study 3051530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (50 mg/day, adjusted up to 100 mg/day)
Number of subjects: 301
Study 3051530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 3051530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 301
Study 30614024 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave-induced combustion (MIC)
Number of subjects: 0